Press "esc" to clear
Go to Advanced Search

Showing results

3140 of 3009
  • Embargo expired:
    4-Jun-2018 9:35 AM EDT

Article ID: 695416

AI Plus Ovarian Suppression Yields Benefit in High-Risk Premenopausal Breast Cancer Patients

Dana-Farber Cancer Institute

Premenopausal women with hormone receptor-positive, HER2-negative breast cancer and a high risk of recurrence who are treated with an aromatase inhibitor plus ovarian function suppression may gain 10 to 15 percent improvement in freedom from distant recurrence at eight years, according to a new clinical trial analysis reported at the annual meeting of the American Society of Clinical Oncology.

Released:
31-May-2018 3:30 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
  • Embargo expired:
    4-Jun-2018 9:00 AM EDT

Article ID: 695476

New Research Sparks Call for Guidelines Around High-Intensity Interval Training

Les Mills

New research has for the first time set a recommended upper limit of High-Intensity Interval Training (HIIT) at 30-40 minutes working out at above 90 percent of the maximum heart rate per week. The study findings – presented by Associate Professor Jinger Gottschall at the 2018 American College of Sports Medicine (ACSM) Annual Meeting this month – provide evidence that any more than 30-40 minutes of HIIT in a maximum training zone per week can reduce performance and potentially result in a greater risk of injury.

Released:
1-Jun-2018 6:00 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
264_ISPOR_KyleKlein_KKP_4567.jpg

Article ID: 695445

ISPOR 2018 Drew Nearly 4000 Stakeholders in Health Economics and Outcomes Research

ISPOR—The Professional Society for Health Economics and Outcomes Research

ISPOR, the professional society for health economics and outcomes research, recently concluded its ISPOR 2018 conference in Baltimore, MD, USA. The conference drew 3741 healthcare stakeholders representing 70 countries from all sectors of healthcare.

Released:
4-Jun-2018 8:05 AM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
  • Embargo expired:
    3-Jun-2018 1:00 PM EDT

Article ID: 695491

Why Do Some Sleep-Deprived People Experience Worse Cognitive Functioning than Others?

Perelman School of Medicine at the University of Pennsylvania

Penn study reveals that microRNAs predict differences in cognitive impairment in memory and attention after sleep deprivation

Released:
1-Jun-2018 4:40 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
127442_Siefker_Radtke_A.jpg
  • Embargo expired:
    3-Jun-2018 10:00 AM EDT

Article ID: 695392

Erdafitinib Shows Promise in Urothelial Cancer Patients with Specific Mutations

University of Texas M. D. Anderson Cancer Center

In an international Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center, treatment with the oral FGFR inhibitor erdafitinib (ERDA) was well-tolerated and achieved a robust response for patients with metastatic urothelial, or urinary tract, cancers harboring mutations in the FGFR3 gene.

Released:
31-May-2018 12:05 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
  • Embargo expired:
    3-Jun-2018 7:30 AM EDT

Article ID: 695398

Landmark Study Finds More Breast Cancer Patients Can Safely Forgo Chemotherapy

Loyola University Health System

A 21-gene test could enable most patients with the most common type of early breast cancer to safely forgo chemotherapy, according to a landmark study published in the New England Journal of Medicine. Loyola Medicine oncologist Kathy Albain, MD, is among the main co-authors.

Released:
31-May-2018 1:05 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
Ross.Camidge.2018.web.jpg

Article ID: 694881

Updated ALEX Trial Results Show Alectinib Further Outpacing Crizotinib in Treatment Naive ALK+ NSCLC

University of Colorado Cancer Center

Dpdated data further consolidate alectinib as the standard-of-care for first-line treatment of ALK+ non-small cell lung cancer.

Released:
3-Jun-2018 7:05 AM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
DiNardo_C.jpg
  • Embargo expired:
    2-Jun-2018 4:00 PM EDT

Article ID: 695393

Study of acute myeloid leukemia patients shows protein inhibitor drug safe and effective with durable remissions

University of Texas M. D. Anderson Cancer Center

Ivosidenib, an experimental drug that inhibits a protein often mutated in several cancers has been shown to be safe, resulting in durable remissions, in a study of acute myeloid leukemia (AML) with relapsed or refractory disease.

Released:
31-May-2018 12:05 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
  • Embargo expired:
    2-Jun-2018 8:00 AM EDT

Article ID: 695365

Genomic Markers Can Predict the Presence of Lynch Syndrome across a Broad Spectrum of Cancers

Memorial Sloan Kettering Cancer Center

Microsatellite instability (MSI) and DNA mismatch repair (MMR) deficiencies can predict Lynch syndrome (LS) across tumor types, according to researchers from Memorial Sloan Kettering Cancer Center (MSK), who presented this retrospective data analysis in a press conference at the annual meeting of the American Society of Clinical Oncology. This finding suggests that LS is linked to more types of cancer than previously thought, prompting a call for germline testing for LS in all individuals with MSI-high (MSI-H)/mismatch repair deficient (MMR-D) tumors.

Released:
2-Jun-2018 8:00 AM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
  • Embargo expired:
    2-Jun-2018 7:30 AM EDT

Article ID: 695424

Blood Test Shows Potential for Early Detection of Lung Cancer

Dana-Farber Cancer Institute

A test that analyzes free-floating DNA in the blood may be able to detect early-stage lung cancer, a preliminary report from the ongoing Circulating Cell-Free Genome Atlas (CCGA) study suggests.

Released:
31-May-2018 3:30 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment

Showing results

3140 of 3009





Chat now!